Literature DB >> 12643418

Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.

Julio C Vasquez1, Anna Vichiendilokkul, Syed Mahmood, Frank A Baciewicz.   

Abstract

Heparin is the standard agent used for systemic anticoagulation during cardiopulmonary bypass in cardiac operations. Alternatives are needed when patients with heparin-induced thrombocytopenia type II are encountered. We present a patient with a clinical picture of heparin-induced thrombocytopenia type II who was effectively anticoagulated with bivalirudin, a direct thrombin inhibitor, during cardiopulmonary bypass for a cardiac operation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643418     DOI: 10.1016/s0003-4975(02)04125-5

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Authors:  Dong-mei Zhang; Kun Wang; Xia Zhao; Yun-fei Li; Qing-shan Zheng; Zi-ning Wang; Yi-min Cui
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

2.  Anticoagulant therapy during cardiopulmonary bypass.

Authors:  Maryam Yavari; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2008-10-19       Impact factor: 2.300

3.  Why is the platelet count low: should I be concerned about heparin-induced thrombocytopenia?

Authors:  Christopher Lancaster; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 4.  Cardiopulmonary bypass in patients with pre-existing coagulopathy.

Authors:  William DeBois; Junli Liu; Leonard Lee; Leonard Girardi; Wilson Ko; Anthony Tortolani; Karl Krieger; O Wayne Isom
Journal:  J Extra Corpor Technol       Date:  2005-03

5.  Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.

Authors:  James J Veale; Harry M McCarthy; George Palmer; Cornelius M Dyke
Journal:  J Extra Corpor Technol       Date:  2005-09

Review 6.  [Direct thrombin inhibitors: pharmacology and application in cardiovascular anesthesia].

Authors:  S A Kozek-Langenecker
Journal:  Anaesthesist       Date:  2008-06       Impact factor: 1.041

7.  Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case.

Authors:  Nicolas Nikolaidis; Theodore Velissaris; Sunil K Ohri
Journal:  Tex Heart Inst J       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.